Profile data is unavailable for this security.
About the company
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
- Revenue in USD (TTM)0.00
- Net income in USD-68.87m
- Incorporated2020
- Employees159.00
- LocationNuvation Bio Inc357 Tehama Street, Floor 3SAN FRANCISCO 94103United StatesUSA
- Phone+1 (415) 754-3517
- Fax+1 (302) 636-5454
- Websitehttps://www.nuvationbio.com/
Mergers & acquisitions
Acquired company | NUVB:NYQ since announced | Transaction value |
---|---|---|
AnHeart Therapeutics Inc | 31.17% | 100.69m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Praxis Precision Medicines Inc | 2.20m | -125.38m | 689.79m | 82.00 | -- | 2.33 | -- | 314.26 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
Hillevax Inc | 0.00 | -143.51m | 699.08m | 90.00 | -- | 2.89 | -- | -- | -3.29 | -3.29 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -46.66 | -- | -50.34 | -- | -- | -- | -- | -- | -- | -- | 0.0963 | -- | -- | -- | 22.68 | -- | -- | -- |
CARGO Therapeutics Inc | 0.00 | -121.21m | 704.67m | 116.00 | -- | 1.62 | -- | -- | -2.91 | -2.91 | 0.00 | 9.48 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
SS Innovations International Inc | 11.22m | -22.75m | 708.57m | 239.00 | -- | 52.35 | -- | 63.16 | -0.1372 | -0.1372 | 0.0698 | 0.0793 | 0.6146 | -- | 2.43 | 46,943.05 | -124.63 | -161.38 | -289.30 | -449.76 | 11.08 | -79.79 | -202.80 | -495.77 | 0.8699 | -57.41 | 0.3901 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Immunome Inc | 12.68m | -232.03m | 721.43m | 55.00 | -- | 2.51 | -- | 56.88 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
Perspective Therapeutics Inc | -304.00k | -48.91m | 722.30m | 116.00 | -- | 2.74 | -- | -- | -1.62 | -1.97 | -0.0092 | 3.92 | -0.0015 | -- | -- | -2,620.69 | -24.10 | -- | -25.46 | -- | -- | -- | -- | -- | -- | -- | 0.0074 | -- | -- | -- | -- | -- | -- | -- |
Savara Inc | 0.00 | -64.49m | 728.40m | 37.00 | -- | 5.02 | -- | -- | -0.3848 | -0.3848 | 0.00 | 0.8819 | 0.00 | -- | -- | 0.00 | -44.84 | -36.86 | -47.26 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1782 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 737.46m | 1.22k | -- | 0.687 | -- | 3.53 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
89bio Inc | 0.00 | -165.03m | 739.85m | 70.00 | -- | 1.40 | -- | -- | -2.01 | -2.01 | 0.00 | 5.36 | 0.00 | -- | -- | 0.00 | -30.80 | -45.50 | -32.70 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0466 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Dianthus Therapeutics Inc | 3.22m | -50.21m | 740.19m | 53.00 | -- | 1.99 | -- | 229.59 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Nuvation Bio Inc | 0.00 | -68.87m | 748.93m | 159.00 | -- | 1.12 | -- | -- | -0.3146 | -0.3146 | 0.00 | 2.71 | 0.00 | -- | -- | 0.00 | -10.84 | -16.27 | -11.09 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
Viridian Therapeutics Inc | 288.00k | -218.13m | 786.29m | 96.00 | -- | 2.05 | -- | 2,730.18 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
AbCellera Biologics Inc | 35.79m | -146.90m | 791.01m | 586.00 | -- | 0.699 | -- | 22.10 | -0.5056 | -0.5056 | 0.1232 | 3.85 | 0.0242 | -- | 1.32 | 61,071.67 | -9.92 | 6.08 | -10.62 | 6.67 | -- | -- | -410.47 | 24.69 | 7.75 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 802.34m | 300.00 | -- | 2.24 | -- | 4.19 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Cogent Biosciences Inc | 0.00 | -212.17m | 806.98m | 164.00 | -- | 4.03 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 27.74m | 11.22% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 19.21m | 7.77% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 10.47m | 4.24% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 7.42m | 3.00% |
Abrams Capital Management LPas of 31 Mar 2024 | 3.81m | 1.54% |
Tang Capital Management LLCas of 31 Mar 2024 | 3.55m | 1.44% |
Geode Capital Management LLCas of 31 Mar 2024 | 3.13m | 1.27% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.04m | 1.23% |
Redmile Group LLCas of 31 Mar 2024 | 3.03m | 1.23% |
Aisling Capital Management LPas of 31 Mar 2024 | 2.54m | 1.03% |